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Summary
The mechanism of toxicity for cytolytic lymphocytes of Leu-Leu-OMe and related dipeptide
derivatives was examined. Selective inhibition of dipeptidyl peptidase I (DPPI), a lysosomal thiol
protease highly enriched in cytotoxic lymphocytes, prevented all natural killer (NK) toxic effects
of such agents. However, many DPPI substrates were found to possess no NK toxic properties.
For some such agents, this lack of NK toxicity appeared to be related to the lack of uptake by
lymphocytes. In this regard, Leu-Leu-OMe was found to be incorporated by lymphocytes and
monocytes via a saturable facilitated transport mechanism with characteristics distinct from previously
characterized mammalian dipeptide transport processes. This novel transport process was found
to be specific for dipeptides composed of selective L-stereoisomer amino acids and enhanced by
hydrophobic ester or amide additions to the COOH terminus of dipeptides. Maximal rates of
Leu-Lcu-OMe uptake by T8 and NK cell-enriched peripheral blood lymphocytes (PBL) were
four- to sixfold higher than for T4-enriched PBL or PBL depleted of Leu-Leu-OMe-sensitive
cytotoxic lymphocytes. All dipeptide amides or esters with NK toxic properties were found to
act as competitive inhibitors of [3H]Leu-Leu-OMe uptake by PBL. However, some NK nontoxic
DPPI substrates were found to be comparable with Leu-Leu-OMe in avidity for this transport
process. Such agents were noted to possess one or more hydrophilic amino acid side chains and
were found not to mediate red blood cell lysis when subjected to the aryl transferase activity
of DPPI. Thus, uptake by a dipeptide-specific facilitated transport mechanism and conversion
by DPPI to hydrophobic polymerization products with membranolytic properties were found
to be common features ofNK toxic dipeptide derivatives. The presence of a previously unreported
dipeptide transport mechanism within blood leukocytes and the selective enrichment of the granule
enzyme, DPPI, within cytotoxic effector cells of lymphoid or myeloid lineage appear to afford
a unique mechanism for the targeting ofimmunotherapeutic reagents composed ofsimple dipeptide
esters or amides.
C
ells with cytotoxic potential contain a unique array of
granule-associated proteins. Thus, specialized cytoplasmic
granules containing pore-forming molecules and other toxins,
have been noted to be common features of cytotoxic effector
cells oflymphoid or myeloid lineage (1-5). A number ofserine
esterases also appear to be selectively expressed within the
lysosome-like granules of cytotoxic lymphocytes (6-10). In
addition, we have recently found that the lysosomal thiolpro-
tease, dipeptidyl peptidase I (DPPI)t is present at far higher
' Abbreviations used in this paper: DPPI, dipeptidyl peptidase 1; M0,
monocytes.
183
levels in cytotoxic lymphocytes than in cells without ryto-
lytic potential or not of bone marrow origin (11).
The presence of high concentrations ofDPPI within cyto-
toxic effector cells was notedin the course of studies designed
to delineate the mechanisms of the toxic effects of L-leucyl-L-
leucine methyl ester (Leu-Leu-OMe) on these cells. The selec-
tive toxic effects of Leu-Leu-OMe on human or murine lym-
phoid or myeloid cells with rytolytic potential had previously
been defined (12-15), and were found to relate to their unique
capacity to metabolize this immunosuppressive agent. After
exposure to Leu-Leu-OMe, cytotoxic lymphocytes generated
membranolytic products of the structure (Leu-Leu)n OMe,
where n >,3 (11) by the aryl transferase activity of the lyso-
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levels in these cells than in cells without cytotoxic potential
(11). Examination of a panel of dipeptide methyl esters for
the capacity to cause similar toxicity toward cytolytic cells
indicated that all active compounds could be substrates for
DPPI (11, 12). However, additional dipeptide esters such as
LeuTyr-OMe or Ser-Leu-OMe, which areputative substrates
for DPPI, were found to cause no toxicity forrytolyticcells
(12). This observation suggested that other properties of
dipeptide esters or other aspects of the processing of these
compoundsmust also be involved in themechanismwhereby
Leu-Leu-OMe and other dipeptide ester substrates of DPPI
selectively kill cytotoxiclymphocytes andmyeloidcells. The
present studies were designed to delineate the metaborsm
of dipeptide esters by cytotoxic cells in greater detail and,
thereby, the mechanism oftoxicity of Leu-Leu-OMeforlym-
phocytes and myeloid cells with cytolytic potential.
Materials and Methods
Medium.
￿
Forcell culture, RPMI 1640 (Hazelton, Dutchland,
Inc., Denver, PA) supplemented with 10% FCS, penicillin G (200
U/ml), gentamicin (10 Wg/ml), and L-glutamine (0.3 mg/ml) was
used.Forincubations with various dipeptidederivatives, PBS sup-
plemented with 1 g/liter glucose was used, except where noted.
Reagents. Leu-Leu-NH2, Gly-Phe-/3-naphthylamide, Gly-Arg-
0-naphthylamide, N-a-benzyloxycarbonyl (Z) Arg-Arg-9-
naphthylamide, and Asp-Phe-OMe were purchased from Sigma
Chemical Co., St. Louis, MO. All other dipeptide methyl esters
were synthesized from appropriate dipeptides (Sigma Chemical Co.)
by esterification in 3 M methanolic HCI, as previously described
(12). ["C]Methanol (ICN Radiochemicals, Irvine, CA) was used
to synthesize ["C]methyl ester derivatives of selected dipeptides.
Purity of [11C]methyl ester derivatives was confirmed by thin layer
chromatography (12). [4,5-'H]Leu-Leu-OMe (60 mCi/mM) was
custom synthesized by New England Nuclear, Boston, MA. Leu-
Leu-OBenzyl andLeu-Leu-NHCH3 were synthesized from amino
acid precursors by C.DeWitt Blanton, University of Georgia Col-
lege of Pharmacy, Athens, GA. The compounds were isolated as
the hydrochloride salts, and the structures were confirmed by
elemental analysis for carbon, hydrogen, nitrogen, and chlorine,
with resultsfound to be within ± 0.4% of theoretical values. The
respective melting points were found to be 144-146*C (Leu-Leu-
OBenzyl) and 223-225°C (Leu-Leu-NHCH3). Gly-Phe-CHN2
was purchased from Enzyme Systems Products, Livermore, CA.
Purified bovine DPPI was purchased from Boehringer Mannheim
Biochemicals, Indianapolis, IN. mAb66.1 (anti-CD4) wasobtained
from hybridoma ascites provided by Patrick Beatty, Seattle, WA,
and OKT4 (anti-CD4), OKT8 (anti-CD8), andL243 (anti-HLA-
DR) were obtained from culture supernatants of hybridoma cells
obtained from the American Type Culture Collection, Rockville,
MD. Leu-11b (anti-CD16) was purchased from Becton Dickinson
Monoclonal Centers, Inc., Mountain View, CA.
Cell Preparations.
￿
PBMC were separated from heparinized ve-
nous blood of healthy donors by centrifugation on sodium dia-
trizoate/ficollgradients (Isolymph; Gallard Schlesinger, Carle Place,
NY). Monocyte (Md)-enriched populations were prepared from glass-
adherent cells, and Mo- and B cell-depleted PBL were prepared from
PBMC by passage through nylon wool columns as described (16) .
CD8* T cell (TS cell)-and NK-enriched lymphocytes were pre-
paredby 66.1 and L243 + C' treatment of PBL, and CD4* T cell
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(T4cell)-enriched lymphocytes were prepared by incubation ofPBL
with OKT8 and L243, followed by panning on goat anti-mouse
Ig-coated petri dishes and treatment with OKT8, Leu-lib, and
C', as previously described (13, 14).
Cytotoxicity Assays.
￿
NK activity against K562 target cellswas
assessed in 4-h"Cr release assays, and percent specific cytotoxicity
was calculated as previously described (16). In other experiments,
human RBC were "Crlabeled and added to microtiter wells (106
RBC/well) in HBSS (200,ul/well) containing 25 mM Hepes and
2 mM DTT and the indicated concentrations of purified bovine
DPPI and dipeptide esters or amides. After incubation for 4 h at
37°C, plates were centrifuged at 50 g for 5min, 100 141 of culture
supernatant were harvested from each well, and "Cr release and
percent specific lysis calculated as previously detailed (16).
Assessment ofCell-associatedPHILu-Leu-OMe.
￿
Cell populations
(2.5 x 106/ml) were incubated at the indicated temperature with
0.2-1 ACi/ml [3H]-labeled Leu-Leu-OMe and the indicated con-
centrations of unlabeled dipeptide esters for fixed time intervals.
Thecells were then centrifuged throughsilicone oil(SF1250; General
Electric Co., Waterford, NY) to separate them from external un-
bound Leu-Leu-OMe. Aliquots of the PBS supernatant and the
cell pellet were then assessed for [3H]Leu-Leu-OMe content by
liquid scintillation spectroscopy. Control tubes to which no cells
hadbeen added were analyzed to quantify theamount ofunbound
[3H]Leu-Leu-OMe that passed through the silicone oil. All assess-
ments were performed in triplicate, and cell-associated [3H]Leu-
Leu-OMe was expressed as mean specific cell-associated [3H]Leu-
Leu-OMe (meancpmbelow silicone in tubeswith cells added - cpm
belowsilicone oil in tubes without silicone oil), or as an absolute
quantity ofLeu-Leu-OMe incorporated as calculated from thefor-
mula: Leu-Leu-OMeincorporated - [(concentration ofLeu-Leu-
OMe) (Volume of totalincubation mixture)] [cpm (cell pellet) -
cpm (background)/cpm (cell pellet) + cpm(supernatant)]. In some
experiments, Leu-Leu-OMeincorporation was assessed over abroad
concentration range, and kinetic constants (Km andVmax) were
calculated from Lineweaver-Buck plots.
Enzyme andProtein Assays.
￿
DPPI activity was assayed fluoro-
metrically at pH 5.0 in 0.05M sodium acetate buffer, 10 mM cys-
teine, 30 mM NaCl, and 1 mM EDTA with Gly-Phe-o-naph-
thylamide as substrate, as previously described (17). In selected
experiments, the acyl transferase activity of DPPI was measured
by incubation of purified DPPI or cell sonicates with 50 mM dipep-
tide ester, 25 mM DTT, 0.4 M hydroxylamine.HCI at pH 6.8 for
20 minat 37°C, as previously detailed (18). Thereaction wasstopped
by addition of equalvolumes of20% trichloroacetic acid. The su-
pernatant was then mixed with 1/2-vol 5% FeC13.6HZ0 in 0.1
M HCl and 1 vol H20, and the absorbance at 510 nM was mea-
sured. Cathepsin B was assayed at pH 6.3 in 0.1 M sodium phos-
phate buffer, 1 mM EDTA, 10 mM cysteine with Z-Arg-Arg-0-
naphthylamide as substrate, as previously described (19). Protein
content was assessed by reaction with bicinchoninic acid, as previ-
ously described (20).
Results
DPPI hasbeen shownpreviously to possess acyl transferase
activity that converts dipeptide amide or dipeptideester sub-
strates to polymerization products of the general structure
(Rl - R2)n - NH2 or (Rt - R2)  - OR3 when RI is not
arginine, lysine, or proline, and RZ is not proline (21-24).
Theacyl transferase activity of DPPI hasbeen demonstrated
to play an essential role in Leu-Leu-014e-mediated toxicityfor human cytolytic cells (11), but its potential role in medi-
ating toxicity of other related compounds has not been de-
termined. The experiments detailed in Table 1 were there-
fore carried out to examine the role of DPPI in the sensitivity
of cytolytic cells to other dipeptide esters or amides. Since
the sensitivity of NK cells to these compounds parallels that
of CTL, for convenience, NK cells were used in these experi-
ments (11, 13).
As demonstrated in experiment 1 (Table 1), incubation of
Table 1.
￿
Dipeptide Methyl Ester-mediated NK Cell Toxicity Is Prevented by the DPPI Inhibitor Gly-Phe-CHN2 and by Ser-Leu-OMe,
but not by Leu-Leu-NH2
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human PBL with 50 p.M Leu-Leu-OMe, Val-Phe-OMe, or
Leu-Phe-OMe for 15 min at room temperature ablated NK
function. The role of DPPI in the action of each of these
dipeptide methyl esters was demonstrated by the finding that
the NK toxic effects ofLeu-Leu-OMe, Val-Phe-OMe, or Leu-
Phe-OMe were prevented by preincubation of PBL with the
irreversible specific inhibitor of DPPI, Gly-Phe-CHN2 (25).
Exposure of human PBL to 10-5 M Gly-Phe-CHN2 for 30
min at 37°C caused >95% inhibition of DPPI activity with
" PBL were suspended at 2.5-10 x 106/ml in PBS and incubated at room temperature for 30 min (Exp. 1) or 15 min (Exps. 2-4) in the
presence of the indicated concentration of the first compound. The second compound was then added to the incubation mixture, and the
cells were incubated for an additional 15 min at room temperature before washing with a greater than fourfold excess of HBSS at 0-4°C.
t Treated cells were resuspended in medium and cultured at 37°C for 2 h before assessment of the capacity to lyse K562 cells at an E/T
ratio of 10:1.
S After 30 min of incubation with diluent control (0.5% DMSO in PBS) or 10-5 M Gly-Phe-CHN2, DPPI activity of the cell lysates was
14.6 and 0.3 nM naphthylamide released per 106 cells/h, respectively, whereas cathepsin B activity was 7.4 and 7.7 nmol naphthyla-
mide/106 cells/h, respectively.
Exp.
Lymphocyte
First addition
preincubation"
Second addition
NK function
(percent specific lysis, K562#)
1 38
50 AM Leu-Leu-OMe 2
50 WM Val-Phe-OMe 3
50 AM Leu-Phe-OMe 2
10-5 M Gly-Phe-CHN25 33
50 AM Leu-Leu-OMe 33
50 AM Val-Phe-OMe 35
50 AM Leu-Phe-OMe 34
2 42
50 AM Leu-Leu-OMe 2
250 AM Ser-Leu-OMe 40
250 AM Leu-Tyr-OMe 43
5 AM Gly-Phe-/3-naphthylamide 0
500 AM Gly-Arg-R-naphthylamide 44
3 51
25 AM Leu-Leu-OMe 16
50 AM Leu-Leu-OMe 4
100 AM Leu-Leu-OMe 2
250 AM Ser-Leu-OMe 54
25 14M Leu-Leu-OMe 58
50 AM Leu-Leu-OMe 53
100 14M Leu-Leu-OMe 26
4 37
50 AM Leu-Leu-OMe 0
1 mM Leu-Leu-NH2 41
50 AM Leu-Leu-OMe 1no significant effect on the activity ofanother lysosomal thiol
protease cathepsin B (Table 1, footnote). These results are
consistent with the conclusion that the capacity of a dipep-
tide methyl ester to serve as a substrate for DPPI was neces-
sary for it to be toxic to NK cells. However, as demonstrated
in experiment 2 (Table 1), exposure of PBL to the putative
DPPI substrates, Ser-Leu-OMe or LeuTyr-OMe (22, 24), did
not cause detectable NK toxicity, even when these compounds
were present at concentrations fivefold higher than concen-
trations of Leu-Leu-OMe that ablated all NK function. DPPI
has been shown to polymerize dipeptide amides as well as
dipeptide esters (23) . Consistent with this, we have found
that both Gly-Phe-/3-naphthylamide and Gly-Arg-a-naph-
thylamide are efficiently degraded by PBL lysates or purified
bovine DPPI, with the latter a better substrate than the former
(data not shown) . Despite this, as demonstrated in experi-
ment 2 (Table 1), NK function was ablated by exposure to
modest concentrations of Gly-Phe-(3-naphthylamide, whereas
Gly-Arg-a-naphthylamide was not NK toxic, even at a 100-
fold higher concentration. In addition, Leu-Leu-NH2, an-
other substrate of DPPI, was not NK toxic at 1 mM, as
demonstrated in experiment 4 (Table 1). These results indi-
cate that substrates of DPPI differ in their capacity to cause
NK cell toxicity. Additional complexity in this system was
indicated by the finding that Ser-Leu-OMe was able to in-
hibit the toxic effects of Leu-Leu-OMe on NK cells, even
though it was not directly toxic for NK cells. Thus, as shown
in experiment 3 (Table 1), PBL were completely protected
from the NK toxic effects of 25-50 AM Leu-Leu-OMe by
250 AM Ser-Leu-OMe, and partially protected from the effects
of 100 AM Leu-Leu-OMe. By contrast, the presence of a 10-
fold excess of Leu-Leu-NH2 (experiment 4, Table 1) afforded
no protection from the NK toxic effects of Leu-Leu-OMe.
The inability of either Ser-Leu-OMe or Leu-Leu-NH2 to
exert toxic effects on NK cells, and the differences in their
capacities to inhibit Leu-Leu-OMe-mediatedNK toxicity, sug-
gested that being a substrate for DPPI was not sufficient for
a dipeptide methyl ester or amide to be toxic for NK cells.
Other features of the molecule appeared to be necessary for
this action.
Other possible steps involved in the toxicity of a dipeptide
methyl ester for NK cells could be the uptake of the com-
pound by the cell and/or the generation of a membranolytic
molecule by the action of DPPI. The next experiments, there-
fore, examined the mechanism ofthe uptake of Leu-Leu-OMe
by humanPBL to determine whether a specific transport mech-
anism was involved. As detailed in Fig. 1, the quantity of
cell-associated [3H]Leu-Leu-OMe increased in a linear, time-
dependent fashion over the first 30 min of incubation ofhuman
PBL with 250 AM Leu-Leu-OMe at room temperature. As
demonstrated in Table 2, when incubations were carriedout
at temperatures <4°C, no accumulation of [3H]Leu-Leu-
OMe by PBL was detected. After incubation at 37°C, levels
of cell-associated Leu-Leu-OMe were increased above those
seen at 22°C (experiment 2, Table 2). These findings sug-
gested that Leu-Leu-OMe was not simply binding to PBL
by an energy- or temperature-independent process. Rather,
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Figure 1 .
￿
Time course of Leu-Leu-OMe incorporation by human
PBL. Human PBL (2.5 x 106/ml) were suspended in PBS containing
0.75 ACi [3H]Leu-Leu-OMe per milliliter and 250 uM unlabeled Leu-
Leu-OMe. At the indicated time points, triplicate 1-ml aliquots of
cell suspensions were centrifuged through silicone oil and cell-
associated [3H]Leu-Leu-OMe was assessed. Values are given for mean
± SE of triplicate determinations.
the time- and temperature-dependent increases in cell-associated
Leu-Leu-OMe suggested that this compound was being in-
ternalized and retained by PBL.
When the concentration dependence of Leu-Leu-OMe up-
take by various subpopulations ofhuman PBMC was assessed
(see Fig. 2), the quantity of Leu-Leu-OMe incorporated during
a 15-min incubation at 22°C was noted to increase in direct
proportion to the external concentrations until 100 AM was
exceeded, at which point the saturable characteristics of this
uptake process became apparent. Differences in the uptake
ofLeu-Leu-OMe by different subpopulations of PBMC were
noted. Thus, T8 and NK cells incorporated three- to four-
fold greater quantities of Leu-Leu-OMe than did T4 cells (see
Fig. 2 and Table 3). Mcc took up an intermediate amount of
Leu-Leu-OMe compared with that taken up by T8- and NK-
enriched cells and T4-enriched cells (Fig. 2 and Table 3) .
Table 2.
￿
Temperature Dependence of(3H]Leu-Leu-OMe
Uptake/Binding by Lymphocytes
' Cell-associated [3H]Leu-Leu-OMe was assessed after 15-min incuba-
tions of PBL with 100 juM Leu-Leu-OMe at the indicated tem-
perature.
Exp. Temperature [3H)Leu-Leu-OMe uptake/binding'
nmol/106 cells
1 0°C 0.05
22°C 0 .77
2 4°C 0.02
22°C 0.31
37°C 0.52m
0
2
TS,NK Celle
Monocytee
T4 Calls
500
￿
1000
￿
1500
Lou-Leu-OMe Concentration (uM)
Figure 2.
￿
Concentration-dependent uptake of Leu-Leu-OMe by
human M0 and lymphocytes. The indicated cell populations were in-
cubated for 15 min at 22°C with varying concentrations of Leu-Leu-
OMe and the quantity of Leu-Leu-OMe incorporated, as detailed in
Fig. 1 and Table 2. Values are given for mean ± SE of triplicate de-
terminations.
Despite the variability in maximal uptake of Leu-Leu-OMe
by the various populations of PBMC, Leu-Leu-OMe incorpo-
ration in all cases was mediated by asaturableprocess with aKm
of 100-200 P.M (Table 3; additional experiments not shown).
To determine whether cells with a greater capacity to take up
Leu-Leu-OMe were the cells selectively killed by exposure to
this agent, PBL were incubated in the presence or absence of
250 fiM Leu-Leu-OMe for 15 min at 22°C and then washed
Table 3.
￿
Rates of Leu-Leu-OMe Uptake and DPPI Content
of Monocytes and Lymphocyte Subpopulations
" Data are provided for the cell populations isolated from a single
peripheral blood sample.
t Kinetic constants calculated by least squares fit in Lineweaver Burk
plots of Leu-Leu-OMe uptake assessed at concentrations of 4, 16,
64, 256 and 1,024 AM. All coefficients of correlation were >0.95.
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and cultured for 18 h at 37°C before assessment of Leu-Leu-
OMe uptake. These treatment conditions have been previously
shownto result in thedeathof20-50% ofPBL(13). Themajority
of PBL, however, remain viable and functionally intact (13).
As illustrated in Table 3, Leu-Leu-OMe-resistant PBL depleted
of NK and CTLby Leu-Leu-OMetreatment (12, 13)were noted
to incorporate Leu-Leu-OMe at approximately half the rate of
untreated control PBL.
As demonstrated by the data detailed in Table 3, cell popula-
tions with higher DPPI concentrations (T8, NK cells, or MO)
generally were found to incorporate [3H]Leu-Leu-OMe at
greater rates than was observed forrelatively DPPI-deficient
T4 cells or Leu-Leu-OMe-treated PBL. Thus, T8- and NK-
enriched PBL were found to contain approximately eight-
fold more DPPI activity and to incorporate Leu-Leu-OMe
at a fourfold greaterrate than did T4-enriched PBL. In addi-
tion, Leu-Leu-OMe-resistant PBL had afour-to fivefold lower
DPPI content and incorporated Leu-Leu-OMe at approxi-
mately half the rate of control PBL. Despite the apparent
correlation between DPPI content and Leu-Leu-OMcincor-
poration, theLeu-Leu-OMe uptake measured in thesestudies
was not simply a reflection ofretention of Leu-Leu-OMeprod-
ucts of DPPI metabolism . Thus, in the experiment detailed
in Fig. 3, unseparated PBL or T8- andNK-enriched popula-
tions were preincubated with 10-5 M Gly-Phe-CHN2. Al-
though incubation with Gly-Phe-CHN2 routinely leads to
>95% inhibition of intracellular DPPI activity (Table 1), Leu-
Leu-OMe uptake by cells treated with this specific DPPI
inhibitor was not significantly altered. Thus, Leu-Leu-OMe
uptake appears to involve mechanisms distinct from the en-
zymatic activity of DPPI.
Peptide transport processes have been described in a va-
riety of mammalian tissues (26). The experiments detailed
in Table 4 were carried out to determine whether theuptake
500
￿
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Leu-Leu-OMe Concentration CUM)
Figure 3.
￿
Concentration-dependent uptake of Leu-Leu-OMe is not
affected by pretreatment with the DPPI inhibitor Gly-Phe-CHN2.
The indicated cell populations were incubated for 1 h in the presence
or absence of 10-5 M Gly-Phe-CHN2 The cells were then washed
and assessed for concentration-dependent Leu-Leu-OMe uptake, as
detailed in Fig. 2.
Kinetics of
Leu-Leu-OMe
uptake#
Cell DPPI
population' content Km Vmax
nmol naphthylamine nmol/
released/106 MIA MM 106 cells/h
T8, NK cells 63.1 152 16.0
MO 25.0 190 9.0
PBL 24 .7 101 5.5
T4 cells 7.7 113 4.1
Leu-Leu-OMe-
resistant PBL 5.6 100 2.7` Leu-Leu-OMe uptake was assessed after incubation of PBL for 15
min at 22°C in the presence of 100 #M Leu-Leu-OMe. Values are
given for mean ± SE of triplicate determinations.
1 PB, phosphate buffer composed of Na2P04 and NaHP04.
of Leu-Leu-OMe by human PBL is mechanistically similar
to dipeptide transport processes previously characterized in
the intestinal tract, renal tubule, or the brain (26-31). Intes-
tinal and renal tubular dipeptide transport has been shown
to be an active proton-coupled process that proceeds optimally
at extracellular pH of 5.5-6 .0 (27, 28, 31). However, as indi-
catedby the results detailed in Table 4, Leu-Leu-OMe uptake
by human PBL is decreased rather than increased when ex-
tracellular pH is decreased from 7.4 to 6.0. Furthermore, rates
of Leu-Leu-OMe uptake were unaffected by addition of the
metabolic inhibitor, sodium azide, or by the presence or ab-
sence ofextracellular glucose or sodium, additionally demon-
strating that its uptake by PBL proceeds by a mechanism that
is different than the aforementioned dipeptide transporters
(26-31).
Additional experiments were carried out to assess the
specificity of this transport process. Various structural ana-
logues of Leu-Leu-OMe were examined for the capacity to
inhibit the uptake of [3H]Leu-Leu-OMe. The results of ex-
periments depicted in Fig. 4 demonstrate that uptake of
[3H]Leu-Leu-OMe is competitively inhibited not only by ad-
dition o£ excess unlabeled Leu-Leu-OMe, but also by excess
unlabeled Val-Phe-OMe or Ser-Leu-OMe. The virtually iden-
tical concentration-dependent patterns of inhibition of
[3H]Leu-Leu-OMe uptake by these three unlabeled dipeptide
methyl esters suggested that these compounds were competing
for a common facilitated transport mechanism. Additional
experiments were carried out to explore the structural char-
acteristics of compounds that competitively inhibit [3H]Leu-
Leu-OMe uptake in greater detail. As demonstrated by the
results in Table 5, [3H]Leu-Leu-OMe uptake is competi-
tively inhibited not only by excess quantities of unlabeled
Leu-Leu-OMe, but also by high concentrations of the dipep-
tide Leu-Leu and by other esters of Leu-Leu such as Leu-Leu-
OBenzyl. However, neither Leu-OMe nor Leu-Leu-Leu-OMe
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Figure 4.
￿
[3H]Leu-Leu-OMe uptake is competitively inhibited by
Leu-Leu-OMe, Ser-Leu-OMe, or Val-Phe-OW PBL (2.5 x 106/ml)
were suspended in PBS containing 0.75 p.Ci/ml [3H]Leu-Leu-OMe
(sp act, 60 mCi/mM) and the indicated concentrations of unlabeled
dipeptide esters. After a 15-min incubation at 22°C, cells were spun
through silicone oil, and [3H]Leu-Leu-OMe incorporation was as-
sessed. Values displayed represent means of triplicate determinations.
In all cases, SEs were <15% of mean values.
were observed to compete with lymphocyte incorporation
of Leu-Leu-OMe. Furthermore, neither the D-stereoisomer
of Leu-Leu-OMe nor the amide analogue Leu-Leu-NH2 in-
hibited uptake ofthe dipeptide methyl ester. Thus, the saturable
process whereby Leu-Leu-OMe is incorporated into PBL is
restricted to dipeptides or dipeptide derivatives.
In addition, as demonstrated by the experiments in Table
6, not all dipeptide methyl esters composed ofL-stereoisomers
of naturally occurring amino acids can effectively compete
with [3H]Leu-Leu-OMe uptake. Thus, excess concentrations
of unlabeled Pro-Leu-OMe or Asp-Leu-OMe had no discern-
ible effect on the uptake of [3H]Leu-Leu-OMe. Of note, nei-
Table 5.
￿
Competitive Inhibition of PHJLeu-Leu-OMe Uptake
by Other Derivatives of Leu-Leu
Percent inhibition of
Unlabeled compound
￿
IIH]Leu-Leu-OMe uptake'
Leu-OMe
￿
-10
Leu-Leu
￿
44
Leu-Leu-OMe
￿
72
D-Leu-D-Leu-OMe
￿
7
Leu-Leu-OBenzyl
￿
87
Leu-Leu-NH2
￿
8
Leu-Leu-Leu-OMe
￿
6
Uptake of 10 pM [3H]Leu-Leu-OMe was assessed in the presence
of 250-AM concentrations of the indicated unlabeled compounds.
Results are the means of two to four separate triplicate determina-
tions . In all cases, SEM was 410%.
Table 4. Metabolic Requirements of Leu-Leu-OMe Uptake by
Human PBL
1500
Composition of
E
incubation medium (150 mM) Leu-Leu-OMe uptake` 0 1000 n
pmol/106 cells/15 min
PBt, pH 7.4 1,344 ± 237
0
m
PB, pH 7.0 717 ± 41 i 500
PB, pH 6.0 412 ± 43
m
J
2
PB, pH 7.4, 0.1% Sodium Azide 1,447 ± ,76
M
PB, pH 7.4, 0.1% Glucose 1,307 ± 136
NaCl, 25 mM Hepes, pH 7.4 1,385 ± 116
CholineCl, 25 mM Hepes, pH 7.4 1,416 ± 132" Assessed as detailed in Table 3. In all cases, SEM was 510%.
t Calculated from previously published data (12) LD50 determined
from the concentration required to ablate 50% of cytotoxicity/activi-
ty of NAC assayed against K562 targets at a 20:1 E/T ratio.
ther Pro-Leu-OMe nor Asp-Phe-OMe caused significant NK
toxicity, whereas compounds such as Val-Phe-OMe and Leu-
Phe-OMe not only shared the NK toxicity ofLeu-Leu-OMe,
but also appear to share the same lymphocyte uptake pathway,
as they are virtually identical to unlabeled Leu-Leu-OMe in
the capacity to inhibit the uptake of [3H]Leu-Leu-OMe.
Lack of affinity for this facilitated transport pathway, how-
ever, could not explain the lack of NK toxicity of LeuTyr-
OMe or Ser-Leu-OMe, as these compounds were noted to
inhibit [3H]Leu-Leu-OMe incorporation very effectively.
The results suggested that for some dipeptide esters such
as Ser-Leu-OMe or LeuTyr-OMe, lack of toxicity for DPPI-
rich cytolytic lymphocytes could not be explained by the in-
ability to be taken up by lymphocytes or by the lack of known
substrate affinity for DPPI. Experiments were therefore car-
ried out to determine whether DPPI-generated metabolites
of such dipeptide esters exhibited membranolytic potential.
As previously reported and as detailed in Fig. 5 (upper left),
when 5'Cr-labeled human RBC were incubated with vary-
ing concentrations ofLeu-Leu-OMe alone or with DPPI alone,
no damage to cell membranes was apparent. However, in the
presence of 250 /AM or more Leu-Leu-OMe and DPPI, lysis
ofRBC was noted. This membranolytic effect has been dem-
onstrated previously (11) to be mediated by Leu-Leu-OMe
polymerization products of the general structure (Leu-Leu)-
OMe, when n >3.
Leu-Leu-NH2 proved to be an equally good substitute for
productionofmembranolytic DPPI metabolites, whereas the
benzyl ester derivative of Leu-Leu was found to be an even
more effective substrate for this process. Substitution of D-
stereoisomers of Leu into both positions of Leu-Leu-OMe
or either the NH2-terminal or penultimate position of this
substrate (data not shown) led to no DPPI-catalyzed mem-
branolytic effects. The lack of RBC lysis in the presence of
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DPPI and D-stereoisomers of Leu-Leu-OMe likely is related
to the fact that the aryl transferase activity of this enzyme
is seen only with dipeptide substrates composed entirely of
L-stereoisomer-containing amino acids (22, 24). However, use
of this assay system in additional experiments revealed that
DPPI-catalyzed RBC lysis was observed when NK-toxic dipep-
tide esters such as Leu-Phe-OMe or Val-Phe-OMe were used,
but not when the putative DPPI substrates Ser-Leu-OMe or
LeuTyr-OMe were used. That compounds such as Ser-Leu-
OMe indeed bind to the active site of DPPI is shown by the
results of the experiment detailed in Fig. 6. In this experi-
ment, excess quantities of Ser-Leu-OMe were noted to in-
hibit RBC lysis mediated by the combination of DPPI and
250-1000 p,M Leu-Leu-OMe. In additional experiments, Leu-
Tyr-OMe also was observed to inhibit RBC lysis mediated
by DPPI + Leu-Leu-OMe (data not shown) .
A number of additional dipeptide esters and amides were
also screened in each of these assays to determine the nature
of active compounds in greater detail. As summarized for
representative compounds in Table 7, competitive inhibition
of [3H]Leu-Leu-OMe uptake was seen with dipeptides or
dipeptide methyl esters composed ofuncharged L-stereoisomer
amino acids. Addition of somewhat more hydrophobic benzyl
esteror R-naphthylamide derivatives favored competition with
the transporter responsible for Leu-Leu-OMe incorporation
by PBL, whereas simple amide or methyl amide derivatives
demonstrated no avidity for this transport system. Only dipep-
tide esters or amides composed entirely of nonpolar R group
L-stereoisomer amino acidswere converted to RBC lytic prod-
ucts by DPPI. Thus, all NK toxic dipeptide derivatives have
been noted to act both as competitive inhibitors of [3H]]Leu-
Leu-OMe uptake by human PBL and to serve as substrates
for DPPI-catalyzed lysis ofhumanRBC. In contrast, all dipep-
tide ester or amides that at a concentration of 250 p,M exert
no effect on NK cell function have proven to be inactive in
one or both of these assays. Finally, NK cells pretreated with
the specific DPPI inhibitor Gly-Phe-CHN2 are resistant to
any discernible toxic effects of any of the dipeptide esters or
amides screened in these studies.
The results summarized in Table 7 imply that Ser-Leu-OMe
and LeuTyr-OMe lack NK toxic effects because DPPI poly-
merization products of these compounds lack membranolytic
effects. To verify that this was the basis for the lack of NK
toxicity of these compounds, the experiments detailed in Table
8 were performed. Uptake of these compounds by cytolytic
cells was directly measured, as was their capacity to serve
as substrates for DPPI-mediated transamidation. The results
of these studies indicate that rates of incorporation of Ser-
Leu-O['°C]Me and LeuTyr-O['4C]Me by T8- and NK-
enriched PBL are comparable with the rate of uptake of Leu-
Leu-O['^C]Me. Furthermore, both of these compounds
served as substrates for transamidation by DPPI or by lysates
of cytotoxic cells. The rates ofDPPI-mediated aryl transferase
activity observed with Ser-Leu-OMe or LeuTyr-OMe as sub-
strates were at least as great as the rates observed with Leu-
Leu-OMe as a substrate. Thus, the results indicate that
Ser-Leu-OMe and LeuTyr-OMe are taken up by T8- and NK-
Table 6. Competitive Inhibition ofPH]Leu-Leu-OMe
by Other Dipeptide Esters
Uptake
Percent inhibition NK
Unlabeled of [3H]Leu-Leu-OMe toxicity#
compound uptake (LD50)
/AM
Pro-Leu-OMe -18 >250
Asp-Phe-OMe 8 >250
Leu-Leu-OMe 72 35
Leu-Phe-OMe 72 29
Val-Phe-OMe 75 24
Ser-Leu-OMe 84 >250
Leu-Tyr-OMe 86 >250enrichedPBL and are suitable substrates for transpeptidation
by the DPPI activity present within cytotoxic lymphocytes.
The inability of the compounds to exert toxicity for cyto-
lytic cells, therefore, appears to result from the lack ofmem-
branolytic properties of the transpeptidation products.
Discussion
The present studies elucidate severalcommon characteris-
tics ofNK toxic dipeptide esters and amides . The results not
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Figure 5 .
￿
RBC lysis is mediated
by DPPI metabolites of some but
not all ester or amide derivatives
of Leu-Leu . s'Cr-labeled human
RBC were incubated in the pres-
ence (O) or absence (') of 8 x
10-4 U/ml of DPPI, and the indi-
cated concentrations of dipeptide
esters or amides for 4 h at 37°C
and were then assessed for percent
specific lysis .
only document the metabolic steps involved in the toxicity
to cytotoxic cells, but have also delineated a new transport
system for dipeptides . The observations indicate that uptake
via a facilitated transport mechanism and conversion to hy-
drophobic polymerization products by the granule protease,
DPPI, are essential steps in the mechanism, whereby dipep-
tide esters mediate toxic effects toward cytolytic lymphocytes .
These findings not only provide a basis for design and syn-
thesis of dipeptide analogues that may mimic the unique im-
munosuppressive effects of Leu-Leu-OMe, but also provide,~ 40000
E
a
U u
m
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O
m
m
U
N
20000
Concentration of Lou-Leu-OMe (AM)
Figure 6.
￿
Ser-Leu-OMe competitively inhibits DPPI-catalyzed
production of membranolytic metabolites from Leu-Leu-OMe. RBC
lysis was assessed as detailed in Fig. 6 in the presence (-) or ab-
sence (----) of DPPI with no competing Ser-Leu-OMe (O) or with
2 mM Ser-Leu-OMe (*) present in the assay. Values are given for
mean ± SE of triplicate determinations.
new insights into the manner in which lymphocytes process
these small peptide derivatives.
It has been demonstrated previously that active transport
of di- and tripeptides occurs in mammalian small intestine,
as well as in tissues or cells isolated from a variety of other
organs (26). A number of pharmaceutical agents of analo-
gous structure, including O-lactam antibiotics and the
angiotensin-converting enzyme inhibitor captopril, are also
transported through these peptide carrier systems (32). Pep-
tide transport in intact small intestine or renal tubules is medi-
ated by an active, low affinity process with a Km in the 5-10
mM range (32-34). When dipeptide transport has been as-
sessed in intestinal or renal brush border vesicles, the Km
of this process has been found to be N1 mM (35). In con-
trast, the present studies indicate that human PBL incorporate
Leu-Leu-OMe via a relatively high affinity transport mecha-
nism with a Km of 100-200 /AM. Furthermore, no change
in the rate of Leu-Leu-OMe uptake by PBL was noted in the
presence of azide and/or in the absence of extracellular glu-
cose or Na'. Thus, we have found no evidence to suggest
that dipeptide or dipeptide ester uptake by human PBL is
an energy-requiring process. Rather, the transport process ap-
pears to facilitatemovement ofmolecules down a concentra-
tion gradient. Thus, when lymphocyte volume estimated by
light scatter was used to determine the overall intracellular
concentration of Leu-Leu-OMe achieved aftera 15-min incu-
bation, it was found to approximate no more than 5% of
the extracellular concentration. Therefore, the present data
regarding lymphocyte uptake of Leu-Leu-OMe are most con-
sistent with a facilitated diffusion process mediated by a high
affinity carrier. Furthermore, the absence of a requirement
for extracellular Na+ and the lack of enhancement of PBL
dipeptide transport in the presence of decreased extracellular
pH suggests that unlike amino acid or dipeptide transport
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in other cell types, Leu-Leu-OMe uptake by PBL was not
coupled to Na+ or H+ gradients (27-31). A high affinity
peptide transport process with Km and Vmax values similar
to those detected in the present studies has been observed
in astroglial-rich brain cell cultures (29). However, dipeptide
uptake by astroglial cells has been demonstrated to be an
energy-dependent process that is inhibited by extracellular
Na' depletion, by inhibition of ATP production, or by the
addition ofa variety of tri- or oligo-peptides (29). Therefore,
this astroglial cell peptide transport system, as well as dipep-
tide transport mechanisms previously characterized in the in-
testine or renal tubule, appear to be distinct from the dipeptide-
specific facilitated transport process elucidated in the present
studies.
Wheras simple dipeptides such as Leu-Leu appear to uti-
lize the same PBL transport process as Leu-Leu-OMe, the
present studies indicate that binding to this transporter is facili-
tated by nonpolar ester or amide additions to the COOH
terminus of dipeptides. The lack of competitive inhibition
of Leu-Leu-OMe uptake by excess concentrations of Leu-OMe
or Leu-Leu-OMe suggests that this transport process is strictly
specific for dipeptide derivatives. As not all dipeptide esters
competitively inhibit Leu-Leu-OMe uptake, the membrane
carrier responsible for this process appears to be selective with
regard to dipeptides that can be transported. In the current
studies, this transport system was assessed for the capacity
to internalize Leu-Leu-OMe and other dipeptide ester or amide
substrates of DPPI. It is also possible, however, that under
physiologic conditions, the same peptide carrier may be respon-
sible for facilitating egress of dipeptide products of protease-
mediated degradation of oligopeptides or proteins.
In addition to characterizing the mechanism for internali-
zation of NK toxic dipeptide derivatives, the present studies
also demonstrate that NK toxicity mediated not only by Leu-
Leu-OMe, but also by a variety of other dipeptide esters or
amides, is prevented by preincubation of these cells with a
specific inhibitor of the lysosomal thiol protease, DPPI. In
previous studies, it has been demonstrated that this enzyme
is responsible for conversion of Leu-Leu-OMe to oligomers
of the general structure (Leu-Leu)-OMe (11). The present
studies confirm that serving as a substrate for the transpepti-
dase activity of DPPI is an essential characteristic ofNK toxic
dipeptide esters or amides. However, this attribute is not
sufficient to induce NK toxic effects. Thus, DPPI substrates
such as Ser-Leu-OMe and LeuTyr-OMe mediated no NK toxic
effects when present at concentrations well in excess of con-
centrations of Leu-Leu-OMe that cause ablation of all NK
activity. These agents are equal to Leu-Leu-OMe in the ca-
pacity to inhibit [3H]Leu-Leu-OMe uptake by PBL, and
therefore appear to utilize the same transport mechanism.
Furthermore, direct measurements ofSer-Leu-OMe and Leu-
Tyr-OMe uptake by PBL reveal that lymphocyte incorpora-
tion rates of these dipeptide esters are equal to or superior
to that of Leu-Leu-OMe. Thus, the lack of NK toxicity is
not related to any inability of NK cells to internalize these
agents. However, unlike Leu-Leu-OMe and other dipeptide
esters or amides composed of amino acids with relatively hy-Table 7.
￿
Comparison oftheAvidityforDipeptide Transport, Conversion by theAcyl Transferase Activity ofDPPI to Membranolytic Products,
and NK Toxicity of Various Dipeptide Derivatives
Dipeptidyl peptidase I
￿
Toxicity for
Competitive inhibition of
￿
catalyzed lysis
￿
Toxicity for
￿
Gly-Phe-CHN2
Compound
￿
['H]Leu-Leu-OMe uptake`
￿
of human RBO
￿
human NK cells5
￿
treated NK cellsll
Leu-Leu-OMe
￿
+ +
￿
+ +
￿
+ +
Leu-Leu
￿
+
￿
-
￿
-
Leu-Leu-NH2 ￿-
￿
+ +
￿
-
Leu-Leu-NHCH3
￿
-
￿
-
￿
-
Leu-Leu-OBenzyl
￿
+ +
￿
+ +
￿
+ +
D-Leu-L-Leu-OMe
￿
-
￿
-
￿
-
L-Leu-D-Leu-OMe
￿
-
￿
-
￿
-
Leu-Phe-OMe
￿
+ +
￿
+ +
￿
+ +
Leu-Tyr-OMe
￿
+ +
￿
-
￿
-
Val-Phe-OMe
￿
+ +
￿
+ +
￿
+ +
Pro-Leu-OMe
￿
-
￿
-
￿
-
Asp-Phe-OMe
￿
-
￿
-
￿
-
Ser-Leu-OMe
￿
+ +
￿
-
￿
-
Gly-Phe-OMe
￿
+
￿
+
￿
+
Gly-Phe-anaphthylamide
￿
+ +
￿
+ +
￿
+ +
Gly-Arg-Onaphthylamide
￿
-
￿
-
￿
-
' Assayed as detailed in Tables 5 and 6; >66% inhibition, + + ; >33% inhibition, +; <33% inhibition, -.
t Assayed as detailed in Fig. 6; >33% RBC lysis at 250 AM, + + ; <33% RBC lysis at 250, >33% lysis at 1 mM, +; <33% lysis at 1 mm, -.
5 NK toxicity assessed as detailed in Table 1. >50% loss of NK function, E/T 10:1 ; dipeptide concentration 50 AM, + + ; <50% loss of NK
function at 50 AM but >50% at 250 AM, +; <50% loss NK function at 500 AM, - .
II Toxicity assessed as above for cells preincubated for 30 min at 37°C with 10-5 M Gly-Phe-CHNz before exposure to 50-500-pM concentra-
tions of the indicated compound.
drophobic R groups, DPPI substrates with polar R group
amino acids in either position do not serve as adequate sub-
stratesforDPPI-catalyzed lysis of RBC. ThesepolarR group-
containing dipeptideesters, however, are capable of competi-
tively inhibiting RBC lysis mediated by the combination of
DPPI and Leu-Leu-OMe, and can serve as substrates for the
acyl transferase activity ofDPPI, as hasbeen previously indi-
cated (22, 24). These results, therefore, suggest that (Ser-
LeU)n-OMe or similar polymers form within the granule
compartment of cytotoxic lymphocytes but have no mem-
Table 8.
￿
Ser-Leu-OMe, Leu-Tyr-OMe, and Leu-Leu-OMe Are Taken up by T8- and NK-enriched PBL and Converted to DPPI-mediated
Transamidation Products at Comparable Rates
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Uptake of 250 AM Ser-Leu-O[t4C]Me (sp act 1.29 mCi/mM), Leu-Leu-O[t4C]Me (sp act 1.74 mCi/mM), and Leu-Leu-O[t4C]Me (sp act
1.34 mCi/mM) by T8- and NK-enriched PBL was assessed during a 5-min incubation at 22°C.
i Purified bovine DPPI was present at a concentration of 10-2 U/ml.
5 T8- and NK-enriched cells (107/ml in saline) were sonicated and mixed with equal volumes of substrate buffer solutions containing 100 mM
dipeptide ester, 50 mM DTT, and 0.8 mM hydroxylamine.HCI. Reactions mixtures containing equal concentrations of TS and NK cell soni-
cates treated with 10-4 M Gly-Phe-CHN2 were used as blanks so that only DPPI-mediated transmidation could be assessed.
Dipeptide ester Rate of uptake by T8, NK cells"
Rate of transamidation
by purified bovine DPPPt by T8, NK Cell sonicatess
pmol/106 cells/5 min nmol hydroxamate/20 min
Ser-Leu-OMe 280 3,660 490
Leu-Tyr-OMe 340 2,450 380
Leu-Leu-OMe 220 1,850 240branolytic properties, and hence, no toxic effects. Thus, the
generation of membranolytic products from dipeptide esters
or amides only occurs with DPPI substrates uniformly com-
posed of hydrophobic amino acids.
Of note, in the 5'Cr-labeled RBC assay in which this
membranolytic effect has been directly observed, DPPI-
catalyzed RBC lysis is only observed in the presence of >250
FAM concentrations ofdipeptide ester or amide substrates. De-
spite this, the calculated intracellular concentration of Leu-
Leu-OMe achieved afterexposure to NK toxic concentrations
of Leu-Leu-OMe may be as low as 1-5 /AM. Several factors
may account for this apparent discrepancy. The lysosomotropic
characteristics ofamino acid and peptide esters have been pre-
viously well characterized (36, 37). Therefore, although av-
erage intracellular concentrations of Leu-Leu-OMe achieved
after exposure of T8- and NK-enriched PBL to 50-100 AM
Leu-Leu-OMe may be only 1-5 IAM, the concentration of
this agent within the DPPI-containing granule compartment
of these cellsmay be much higher. In addition, introduction
of membranolytic extensively hydrophobic (Leu-Leu)n OMe
metabolites into appropriate cell membranes may be far more
efficient when these DPPI products are produced within a
cell rather than in the external aqueous medium used in the
5'Cr-labeled RBC lysis assays. These results, therefore, are
still consistent with a primary role for the membranolytic
effects of (Leu-Leu)oOMe products in the generation of
Leu-Leu-OMe-mediated killing of cytolytic lymphocytes. It
remains to be determined whether the membranolytic (Leu-
Leu),;OMe, n >3 products of this enzyme trigger other
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